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Abstract
Background: Nonclinical studies indicate that the hormone relaxin is a good candidate for a safe cervical ripening
agent that does not cause uterine contractions.
Methods: This Phase II study (conducted November 2, 2005–October 20, 2006) was a randomised, double blind,
placebo controlled trial testing 24-h intravenous infusion of serelaxin (recombinant human relaxin) or placebo for
cervical ripening in 72 healthy, primiparous women. Eligible subjects had a singleton pregnancy ≥40 weeks, were
planned for elective induction, had vertex presentation of the fetus, intact membranes and a Bishop score at
screening ≤4. In Part A of the study, safety evaluation of three escalating doses of serelaxin (7.5, 25 or 75 μg/kg/
day) or placebo was performed in 22 subjects admitted to the hospital 24 h prior to scheduled induction (n = 7, 4,
4, and 7 subjects, respectively). The highest safe dose from Part A and placebo were then tested in Part B for safety
and cervical ripening (n = 25 subjects/arm). Planned randomisation ratio was of 4:2 (serelaxin:placebo) for each dose
group in Part A and 1:1 for Part B. For analysis, subjects in Part B were pooled with those receiving the same dose
in Part A and all subjects receiving placebo were pooled. The primary efficacy endpoint was change from baseline
in Bishop score at 6, 12 and 24 h or end of study drug administration. Maternal safety evaluations included adverse
events and vital signs through 4 weeks. Fetal assessments included serial heart rate monitoring and nonstress
testing. Neonatal assessments included Apgar scores, NICU admissions, and adverse events through 4 weeks.
Results: Overall, 74 subjects were randomized and 72 were treated. There were no significant differences between
the groups receiving the highest safe dose of serelaxin (75 μg/kg/day) and placebo in the primary or secondary
efficacy endpoints. Changes from baseline in Bishop score at 24 h were 4.19 ± 1.9 and 3.26 ± 2.26 in the pooled
placebo and serelaxin groups, respectively (p = 0.2507). Serelaxin was well tolerated and no anti-serelaxin antibodies
were detected in either subjects or neonates.
Conclusion: Serelaxin infusion at the end of pregnancy was well tolerated but did not advance cervical ripening.
Trial registration: Clinicaltrials.gov identifier NCT00259103 (15 November 2005).
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Background
Induction of labour is one of the most common proce-
dures in obstetrics, being performed in approximately
25 % of women in industrialized countries [1]. In women
with a high degree of cervical ripeness, induction of
labour can usually be achieved with simple types of
intervention [2]. Conversely, if the cervix is not ripe,
induction of labour is much more likely to fail. In
order to facilitate cervical softening, thinning and
dilation for the purpose of enabling labour induction,
both mechanical and pharmacologic ripening agents
are utilized [2]. Prostaglandins are the most com-
monly used pharmacological aid and are effective in
cervical preparation but are also associated with an
increased risk of uterine hyperstimulation, potentially
leading to fetal heart rate changes [2–4]. Estrogens,
nitric oxide donors, and hyaluronidase have also been
postulated as potential cervical ripening agents but
currently, none are recommended for use in this re-
gard [2, 4]. Therefore, there is still a need for a cer-
vical ripening agent that does not cause uterine
contractions.
The naturally occurring hormone, relaxin, which me-
diates the hemodynamic changes that occur during preg-
nancy [5], causes cervical ripening in rodents and pigs
[6]. In these species, serum relaxin is present from mid-
pregnancy and increases markedly at the end of preg-
nancy in an “antepartum surge” that contributes to cer-
vical ripening. Blocking relaxin activity using anti-relaxin
neutralizing antibodies at this time inhibits cervical rip-
ening in rats [7]. Relaxin- or relaxin receptor gene-
deficient mice demonstrate an impaired ability to deliver
pups, largely due to defective cervical ripening [8, 9]. In
mice, relaxin causes a reduction in the density of colla-
gen fibers [10], an alteration in aquaporin expression
and an increase in hyaluronic acid content in the cervix
[11]. These changes are associated with softening and in-
creased distensibility of the cervix [12].
Although reports regarding the association between
endogenous circulating relaxin levels and cervical ripen-
ing in women have generally shown a lack of correlation
[13–17], relaxin binding sites are detected in the human
cervix [18] and relaxin increases the expression of
matrix metalloproteinases and glycosaminoglycans in
cultured human cervical cells [19].
For these reasons, whether relaxin can cause cervical
ripening has long been of clinical interest [20]. Multiple
clinical trials have been conducted in the past to assess
the ability of relaxin to enhance cervical ripening in a
clinical setting [20–24]. Of these, a Cochrane review [25]
included 4 blinded, randomized studies that tested intra-
cervically and intravaginally administered purified por-
cine or recombinant human relaxin versus placebo and
concluded that the data in these studies were not
sufficient to recommend using relaxin to enhance labour
or ripen the cervix. Pharmacokinetic analysis of intracer-
vical and intravaginal application of serelaxin indicated
that absorption via these topical routes is limited [26],
suggesting that inadequate dosing may have played a
role in the observed lack of efficacy. Therefore, whether
relaxin can indeed ripen the cervix in women remained
an open question.
We report the results of a completed clinical trial,
which is listed in the Cochrane review as awaiting re-
sults [25] and tested intravenous (IV) administration of
recombinant human relaxin (termed “serelaxin,” the
international nonproprietary name) versus placebo for
the ability to ripen the cervix in late pregnant women.
The specific trial objectives were: (1) to test the safety of
24-h IV serelaxin at pharmacological levels in pregnant
women at ≥40 weeks’ gestation, and (2) to determine
whether this mode of dosing could ripen the cervix and
induce labour in these women.
Methods
This study was a prospective, randomized, double-blind,
placebo-controlled pilot Phase II trial evaluating sere-
laxin for safety and efficacy in women ≥40 weeks gesta-
tion admitted for elective induction of labour
(clinicaltrials.gov identifier NCT00259103). It was con-
ducted at 12 clinical sites, including teaching and com-
munity hospitals, in Russia between November 2, 2005
and October 20, 2006 in compliance with the protocol,
International Conference on Harmonization, Good
Clinical Practices, Ministry of Public Health and Social
Development of the Russian Federation, local regulations
and the standard operating procedures of the study
sponsor, Corthera, Inc. (formerly BAS Medical). The
protocol and informed consent were approved by the
governing Ethics Committee at each study site and the
Russian Federal Body for the Control of Pharmaceutical
Agents. Subjects were screened for eligibility in ap-
proved clinics and hospitals by a small number of nurses
or physicians specifically trained on the protocol and
study logistics, including standardized assessment of the
Bishop score [27]. Written informed consent was ob-
tained from each patient before any study-related activity
which was not part of routine care was undertaken, in-
cluding the performance of diagnostic procedures to de-
termine eligibility. The consent allows for publication of
the study data.
Eligible patients were healthy primiparous women,
18–40 years old with a singleton pregnancy, at ≥40 weeks
gestation, as defined by the date of the last menstrual
period. Inclusion criteria included a Bishop score ≤4, in-
tact membranes, vertex presentation of the fetus, < 8
uterine contractions per hour, a reactive fetal nonstress
test, a pre-pregnancy BMI ≤29 and a weight gain ≤18 kg
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during pregnancy. Exclusion criteria included hemoglobin
<8.5 gm/dL, current diagnosis of hypertension, pre-
eclampsia, weight <50 kg, planned and/or prior caesarean
delivery or prior classical uterine incision, malpresentation
of fetus, prolapsed umbilical cord, known fetal anomaly,
or intrauterine growth restriction.
Study design
Eligible subjects were admitted 24 h prior to planned in-
duction and assigned to receive serelaxin or matching
diluent (placebo). Block randomisation was used for Part
A with a ratio of 4:2 (serelaxin:placebo) per dose group
and simple randomisation with a 1:1 ratio was used for
Part B; no stratification variables were implemented. The
randomisation scheme was generated by a contract re-
search organization, Health Decisions Ltd. (Abingdon,
UK), by personnel not involved in day-to-day conduct or
monitoring of the study. Sites received randomisation
numbers via secure web access centrally managed by
Health Decisions. Upon subject randomisation, regional
central pharmacies independent of the clinics and hospi-
tals at which subjects were enrolled prepared study drug
(provided by Corthera) and provided it in identical syrin-
ges labeled in blinded fashion to the study sites. Investi-
gators, site personnel involved in treating and assessing
patients, study operations personnel, including study
monitors and medical monitors, and study subjects were
blinded to treatment assignments.
The study was conducted in two parts:
Part A was a multi-center, randomized, double-blind,
placebo-controlled, sequential dose escalation study
evaluating the safety of 24-h continuous IV serelaxin at
7.5, 25, and 75 μg/kg/day, starting with the lowest dose.
Study drug was infused using a syringe pump with in-
fused volumes identical among all serelaxin doses and
placebo to prevent unblinding. Doses were selected
based on the safety profile and pharmacokinetic param-
eters observed in pregnant monkey studies [28–30], as
well as in previously completed clinical trials in healthy
volunteers or in other indications [26, 31]. Eighteen
subjects were planned to be treated in cohorts of 6 and
randomly assigned to receive serelaxin or placebo in a
4:2 ratio, respectively, in each cohort. Escalation to the
next dose cohort occurred once maternal, fetal and
neonatal safety data, including the one week postpar-
tum assessments, were reviewed in blinded fashion by
the study’s medical monitors and found to be accept-
able. Safety data evaluated included maternal, fetal and
neonatal adverse events (AEs), vital signs, laboratory
findings and physical examination. Dose escalation was
not to occur if new, clinically significant findings indi-
cating increased maternal, fetal or neonatal risk were
observed. The highest safe dose of serelaxin (maximum
tolerated dose [MTD]) was to be further studied for ef-
ficacy, as well as safety, in Part B.
Part B assessed the safety and efficacy of the MTD of
serelaxin and was a multi-center, randomized, double-
blind, placebo-controlled, parallel-group study of 50
subjects randomized in a 1:1 ratio to serelaxin or to
placebo. In both Parts A and B of the study, dosing was
to be discontinued for onset of active labour, uterine
hyperstimulation and abnormal fetal heart rate, or
spontaneous rupture of membranes.
Because the rate of cervical ripening potentially in-
duced by serelaxin was unknown, three time points
within the 24 h treatment period were specified and the
primary efficacy endpoint was change from baseline in
Bishop score at 6, 12 and 24 h (or end of study drug ad-
ministration). As a pilot study, this trial included mul-
tiple exploratory secondary efficacy endpoints, including
proportion of subjects with Bishop score change >3.0,
time to full dilation (>10 cm), time to delivery (vaginal
or C-section), incidence of vaginal deliveries and spon-
taneous labour, and time to onset of active labour, were
also collected in this study. The 24-h changes from base-
line in individual components of the Bishop score were
calculated post-hoc. The sample sizes in Part A were se-
lected empirically. The sample size estimates for Part B
were based on available data from previous trials of
post-date pregnant women [24, 32, 33]. A mean baseline
Bishop score of three and a mean change of three in the
placebo group were estimated. Since there is no previous
clinical experience with systemically administered sere-
laxin in cervical ripening, an estimated mean change in
the active group of six, achievable by prostaglandins
[32], was used. Thus a sample size of 25 per group in
Part B has an 83 % power to detect a difference of 3.0 in
Bishop score between groups in Part B with an alpha of
0.05. This sample size was also estimated empirically to
allow observation of differences between serelaxin and
placebo on a number of clinically relevant endpoints.
Safety
Maternal safety was assessed by monitoring for AEs,
physical examination, ECG and vital signs at screening,
baseline, serially during dosing and through 24 h post-
dosing and at 2 days, 1 week and 4 weeks post-partum.
Clinical chemistry and hematology were assessed at
baseline, 12 and 24 h following initiation of dosing, and
2 days, 1 week and 4 weeks postpartum. Fetal heart rate
was monitored pre-dose and hourly from the start of
dosing to 24 h and hourly from the start of active labour
until delivery. Non-stress testing was performed pre-
dose and at 12 and 24 h during dosing. Neonatal safety
was assessed by 1 and 5-min Apgar scores, admission to
a neonatal intensive care unit (NICU) and vital signs at
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delivery, 2 days, 1 week and 4 weeks post-partum. Inten-
sity of AEs was categorized by investigators using the
following definitions:
 Mild: Usually transient requiring no special
treatment; does not interfere with usual status or
activities; awareness of event but easily tolerated
 Moderate: May be ameliorated by simple
therapeutic measures; may cause enough discomfort
to interfere with usual activities
 Severe: Causes inability to perform usual activities,
requires close monitoring and/or intervention
 Very severe: Significantly debilitating or
incapacitating despite symptomatic therapy, requires
immediate intervention or emergency treatment,
may be life-threatening
Serum serelaxin was measured in subjects prior to
treatment and at 4, 12, and 24 h after initiation of dos-
ing, 24 h after the end of dosing and in cord blood at de-
livery. Anti-serelaxin antibodies were measured in serum
samples collected 1 and 4 weeks after delivery in sub-
jects and in neonates.
Statistical analysis
For efficacy endpoint analysis, all subjects randomized to
the placebo groups in Parts A and B were pooled
(“pooled placebo”) and all subjects receiving serelaxin in
Part B were pooled with subjects in Part A receiving the
same dose (“pooled MTD”). Because of the exploratory
nature of the study, which was intended to aid in endpoint
identification and sample size estimates for a subsequent
larger study, this pooling was reasonable to slightly in-
crease the power to detect differences. To explore the effi-
cacy of a longer duration of dosing for advancement in
Bishop score, a “Per Protocol” (PP) population receiving
≥18 h of study drug was pre-specified. For analysis of
safety, all randomized subjects receiving any amount of
study drug were included.
Data analysis was conducted by SciAn Services (Toronto,
Canada), a contracted data management organization. The
database was locked prior to unblinding and no changes
were made to the database after unblinding. Wilcoxon
rank-sum test was used to assess the difference in change
in Bishop score. Student’s t-test or Chi-square test assessed
differences in secondary end points. A p value <0.05 was
considered significant.
For hematology, chemistry, vital signs, physical exam-
ination and ECGs, summary statistics were provided for
baseline and changes from baseline at each time point
by treatment group.
Maternal AEs were recorded according to time of on-
set, i.e. dosing period (0–24 h), 24-h post-infusion (24–
48 h) and follow-up (>48 h). AEs reported in fetuses and
in neonates were summarized by treatment group. AEs
were coded using the standardized MedDRA dictionary.
Relaxin and anti-relaxin antibody assays
Serum serelaxin was measured in an ELISA validated for
measurement of serelaxin in human serum (sensitivity
96 pg/mL) and according to Good Laboratory Practices
(GLP). Because serelaxin is identical to endogenous
relaxin-2, both are recognized by the assay and results
are presented for “serelaxin and relaxin”.
A GLP screening assay validated for measurement of
serum antibodies to human serelaxin was used. If posi-
tive, samples were to be titered and checked for specifi-
city by inhibition of binding with serelaxin.
Results
A total of 74 subjects were randomized (Fig. 1). Two sub-
jects went into spontaneous labour post-randomisation
before treatment initiation and are excluded from all ana-
lyses. Seventy-two subjects were treated as randomized
(“All Treated” population), 40 with serelaxin and 32 with
placebo. Demographics were similar among subjects ran-
domized to the two groups. Overall, the average age of the
study population was 24 years with means of a BMI of
26 kg/m2, a pre-pregnancy weight of 60 kg, were at
40.6 weeks’ gestation, 85 % were Caucasian and 15 % were
Asian. The average Bishop score was 2.1 ± 1.5 (mean ±
SD) at both screening and at the pre-dose assessment.
Study drug was stopped prior to 24 h due to labour
onset in 4 (13 %) and eight subjects (20 %) in the pla-
cebo and serelaxin groups, respectively. Drug was also
discontinued due to rupture of membranes in one sub-
ject in each of the placebo (6 %) and serelaxin (5 %)
groups. Fifty-six of the 72 subjects (78 %) received ≥18 h
of study drug infusion (PP population).
Part A: Six subjects were randomized to the first
cohort of Part A and an additional 4 were enrolled
during the safety assessment period (Fig. 1). There-
fore, in the first cohort, seven subjects received
7.5 μg/kg/day serelaxin and three subjects received
placebo. The maternal, fetal and neonatal safety data,
including AEs, vital signs, laboratory findings and
physical examination, were found to be acceptable, so
six subjects were randomized to the second cohort,
receiving 25 μg/kg/day relaxin (n = 4) or placebo (n =
2). Once safety in these subjects was affirmed, six
subjects were dosed with 75 μg/kg/day serelaxin (n =
4) or placebo (n = 2) in the third cohort. Based on
the acceptable safety data from the 22 subjects in
Part A, including similar types and distribution of
AEs between groups and few AEs occurring in more
than one individual, the 75 μg/kg/day serelaxin dose
was determined to be the MTD and selected for
study in Part B.
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Part B: Fifty patients were enrolled in Part B.
Serelaxin-treated subjects in Part B (n = 25) were pooled
with subjects in Part A who received the same serelaxin
dose of 75 μg/k/day (n = 4) for a total of 29 subjects in
the pooled MTD group, and all subjects receiving pla-
cebo in Parts A (n = 7) and B (n = 25) were pooled for a
total of 32 subjects in the pooled placebo group (Fig. 1).
The mean treatment duration (mean ± SD) was similar in
the serelaxin (22.3 ± 4.2 h) and placebo groups (21.4 ±
6.1 h). Baseline characteristics of subjects enrolled in the
pooled MTD and placebo groups were similar. The aver-
age ages were 24 and 25 years, with a BMI of 26 and
27 kg/m2, respectively, and both groups were at an aver-
age of 40.6 weeks’ gestation. Ninety and 91 % were
Caucasian in the pooled MTD and placebo groups, re-
spectively, and 3 % were Asian in both groups.
The average Bishop score (mean ± SD) at baseline in
the All Treated population was 2.2 ± 1.3 vs. 1.9 ± 1.6 in
the pooled MTD and pooled placebo groups, respect-
ively (p =NS) (Table 2). There were no statistically sig-
nificant differences between groups in changes from
baseline in Bishop score at any time point or when mea-
sured immediately prior to cessation of dosing (Table 1).
Changes from baseline in Bishop score at 24 h in the All
Treated population were 4.19 ± 1.9 and 3.26 ± 2.26 in the
pooled placebo and serelaxin groups, respectively (p =
0.2507). In the PP population, the mean baseline Bishop
score measured 2.1 ± 1.3 in the pooled placebo group
and 1.6 ± 1.6 in the pooled MTD group (p =NS). At the
12 h time point, the increase from baseline in Bishop
score was larger in the pooled placebo than in the
pooled MTD group (p = 0.0418). No other differences
between the two groups were observed. A post-hoc ana-
lysis of the changes from baseline in the individual com-
ponents of the Bishop score revealed no significant
differences between the pooled placebo and MTD
groups in any of the components (Table 2). None of the
secondary efficacy endpoints showed differences be-
tween the pooled placebo and pooled MTD groups
(Table 3).
The treatment groups showed similar chemistry and
hematology characteristics. Serum creatinine and BUN
Fig. 1 Trial profile (CONSORT 2010). PP Per protocol (received ≥18 h of study drug infusion). *All subjects were treated as allocated
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trended lower in the MTD group than in the placebo
group at the 12 and 24 h time points; none of the differ-
ences were statistically significant except for lower BUN
in the MTD group at the 24 h measurement (p = 0.02).
Mean decreases from baseline in systolic blood pressure
(SBP) during dosing were consistently slightly greater
but not statistically different in the MTD group
compared to the placebo group at all time points after
10 min. No consistent changes in heart rate were noted
in study subjects or fetuses, either during or post-dosing.
Serum serelaxin + relaxin concentration (mean ± SEM)
in the pooled MTD group was 8.27 ± 1.10 ng/mL at the
4-h and 13.03 ± 1.49 ng/mL at the 12-h time point
(Fig. 2). Levels in the placebo group reflecting endogen-
ous relaxin at these time points were 0.44 ± 0.19 and
0.27 ± 0.03 ng/mL, respectively. Levels were below the
detection limit of the assay in the majority of cord blood.
No anti-relaxin antibodies were detectable in any of the
subjects or neonates either at 1 week or 4 weeks post-
partum.
Safety
Safety was assessed in all subjects receiving any amount of
study drug (n = 32 in the pooled placebo group and n = 40
in the pooled serelaxin group). Serelaxin was well toler-
ated in subjects, fetuses and neonates; AEs were generally
balanced between treatment groups. Sixteen subjects, 8
(20.0 %) and 8 (25.0 %) in the serelaxin (all doses) and pla-
cebo groups, respectively, had 19 AEs during the 24-h
dosing period. The most common maternal AE during
Table 1 Mean changes from baseline in bishop score in the all treated and per protocol (PP) populations
Mean ± SD
Active (μg/kg/day)
Part A Part B Pooled MTDa Pooled Placeboa
7.5 25 75 75 75 Placebo
All Treated population
N 7 4 4 25 29 32
Baseline 2.6 ± 1.6 2.5 ± 1.9 2.5 ± 1.9 2.2 ± 1.2 2.2 ± 1.3 1.9 ± 1.6
Change from Baseline:
6 h 1.29 ± 0.95 1.25 ± 0.96 1.50 ± 1.91 1.56 ± 2.20 1.55 ± 2.13 1.77 ± 1.45
12 h 2.43 ± 1.13 2.25 ± 1.71 2.00 ± 1.63 2.13 ± 2.11 2.11 ± 2.02 2.64 ± 1.64
24 h 3.20 ± 0.84 3.00 ± 4.24 2.50 ± 1.91 3.42 ± 2.34 3.26 ± 2.26 4.19 ± 1.90
Last observationb 3.43 ± 0.79 2.75 ± 2.50 2.50 ± 1.91 3.76 ± 2.57 3.59 ± 2.50 4.03 ± 1.90
PP population
N 5 2 4 19 23 26
Baseline 3.0 ± 1.7 2.0 ± 2.8 2.5 ± 1.9 2.0 ± 1.2 2.1 ± 1.3 1.6 ± 1.6
Change from Baseline:
6 h 1.00 ± 0.71 1.00 ± 1.41 1.50 ± 1.91 0.84 ± 1.21 0.96 ± 1.33 1.65 ± 1.38
12 h c 1.80 ± 0.45 2.00 ± 2.83 2.00 ± 1.63 1.63 ± 1.67 1.70 ± 1.64 2.62 ± 1.60
24 h 3.20 ± 0.84 3.00 ± 4.24 2.50 ± 1.91 3.42 ± 2.34 3.26 ± 2.26 4.19 ± 1.90
Last observationb 3.20 ± 0.84 3.00 ± 4.24 2.50 ± 1.91 3.42 ± 2.34 3.26 ± 2.26 4.19 ± 1.90
The Bishop score ranges from 0 (absence of any cervical changes) to a maximum of 13, representing a cervix that is dilated (>5 cm), effaced (>80 %), soft, at a +1
or +2 station, and anteriorly positioned. 26 If the total Bishop score was calculated >13, then ‘13’ was used. Change was calculated as Bishop score at time point –
Bishop score at baseline. All Treated population includes all patients treated with any amount of study drug. Per protocol (PP) population includes all patients
treated for at least 18 h of study drug
aPooled Maximum Tolerated Dose (MTD) group includes subjects who were administered the 75 μg/kg/day dose in Parts A and B of the study. Pooled placebo
group includes all subjects who received placebo in Parts A and B
bLast observation was defined as the last available value observed during dosing
cDifference between the pooled MTD and pooled placebo groups at 12 h, p = 0.042 by Wilcoxon Rank Sum test. No other differences were significant
Table 2 Mean changes from baseline in components of the






Cervical Dilatation (cm) 0.63 ± 0.81 1.35 ± 1.21
Effacement (%) 0.43 ± 0.59 0.65 ± 0.75
Station 0.50 ± 1.45 0.44 ± 0.71
Consistency 0.83 ± 0.78 0.92 ± 0.63
Position of Cervix 0.83 ± 0.83 1.19 ± 0.69
Mean changes from baseline in the individual components of the Bishop score
at 24 h were calculated post-hoc in all patients receiving 24 h of study drug
with Bishop scores available at baseline and 24 h
aPooled Maximum Tolerated Dose (MTD) group includes subjects who were
administered the 75 μg/kg/day dose in Parts A and B of the study. Pooled
placebo group includes subjects who received placebo in Parts A and B
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dosing was tachycardia of mild severity (Table 4). AEs oc-
curred in slightly more subjects in the pooled placebo (12
[38 %]) than pooled serelaxin (9 [23 %]) group during the
24 h post-infusion period, as well as during the follow up
period (17 [53 %] and 19 [48 %] in the placebo and sere-
laxin groups, respectively).
There were no maternal, fetal or neonatal deaths in
the study. One maternal serious AE (SAE) was reported,
cephalopelvic disproportion of moderate severity in a
subject receiving placebo, occurring during labour and
delivery. A C-section was performed and the subject
recovered.
AEs occurred in 16 fetuses, 9 (22.5 %) in the serelaxin
and 7 (21.9 %) in placebo groups and were balanced be-
tween groups (Table 5). SAEs (all considered unrelated
to study drug) were reported in three fetuses: acute fetal
distress of moderate severity in the placebo group and
two SAEs of fetal hypoxia of moderate severity in the
serelaxin group, neither of which required action or
medication; all fetuses recovered. All fetuses had reactive
results at 12 and 24 h, with the majority having reactive
results within the first 20 min and all within 40 min.
AEs were reported in 39 neonates, 19 (47.5 %) in the
serelaxin and 20 (62.5 %) in the placebo groups. The
most common AE was cerebral ischemia (8/32 [25 %] in






Proportion of Subjects with 24 h Change from Baseline in Bishop Score >3b 13/23 (56.5 %) 18/26 (69.2 %) 0.36
Incidence of Spontaneous Labourd 12 / 29 (41.4 %) 20 / 32 (62.5 %) 0.12
Incidence of Vaginal Deliveriesd 20 / 29 (69.0 %) 27 / 32 (84.4 %) 0.15
Time to Vaginal Delivery, Mean ± SDc 62.3 ± 40.2 h 54.3 ± 29.3 h 0.64
Time to Delivery (Vaginal + C-section), Mean ± SDc 66.8 ± 39.6 h 54.5 ± 30.1 h 0.25
Time to Complete Dilation (10 cm), Mean ± SDc 57.5 ± 39.5 h 52.7 ± 26.2 h 1.00
Time to Onset of Active Laboure, Mean ± SDc 53.2 ± 36.3 h 45.8 ± 29.9 h 0.41
aPooled Maximum Tolerated Dose (MTD) group includes subjects who were administered the 75 μg/kg/day dose in Parts A and B of the study. Pooled placebo
group includes all subjects who received placebo in Parts A and B
bSubjects included have Bishop scores available at both baseline and 24 h
cp value was calculated using the Wilcoxon Rank-sum test
dp value was calculated using the Chi-square test
eActive labour was defined as having 35–45 s contractions every 3 min with 4 cm dilation
Fig. 2 Plasma concentrations of relaxin and serelaxin. Plasma levels
of relaxin + serelaxin (mean ± SEM), measured at baseline (0) and at
6, 12, and 24 h from the start of study drug administration in
primiparous women ≥40 weeks of pregnancy in the pooled placebo
and pooled MTD serelaxin groups. In the placebo group, only
endogenous relaxin-2 is measured, while in the pooled MTD group,
both serelaxin and endogenous relaxin-2 are detected
Table 4 Maternal adverse events
Observation Period
Adverse Event Preferred Term






Tachycardia 4 (12.5) 2 (5.0)
24-h Post-infusion
Amniotic fluid decreased 3 (9.4) 0 (0.0)
Labour complication 3 (9.4) 0 (0.0)
Post-partum vaginal
laceration
3 (9.4) 2 (5.0)
Uterine cervical laceration
during labour
4 (12.5) 2 (5.0)
Uterine hypotonus 2 (6.3) 3 (7.5)
>48-h Post-infusion (follow-up)
Amniotic fluid decreased 4 (12.5) 3 (7.5)
Uterine cervical laceration
during labour
6 (18.8) 4 (10.0)
Uterine hypotonus 2 (6.3) 3 (7.5)
Uterine hemorrhage 3 (9.4) 0 (0.0)
Listed are all adverse events occurring in >5 % in either arm during study
drug dosing, within the 24-h post-infusion period and within the follow
up period
aThe pooled placebo group includes all subjects from Parts A and B treated
with placebo and the pooled serelaxin group includes all subjects from Parts A
and B treated with any dose of serelaxin
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the placebo group and 3/40 [7.5 %] in the serelaxin
group) (Table 5). Eleven SAEs (all determined to be un-
related to study drug) were reported in three neonates
(9.4 %) in the placebo and 5 (12.5 %) in the serelaxin
group. All neonates recovered from the SAEs, except for
macrostomia, which was ongoing at the end of the
study. Average Apgar scores were in the normal range,
≥7, for all neonates. Four NICU admissions occurred in
each treatment group. At 1 week, two neonates in the
placebo group remained in the NICU and at 4 weeks,
one remained.
Discussion
This study was the first to test the ability of serelaxin
systemically administered at the end of pregnancy to
ripen the cervix. Unlike the topical modes of administra-
tion used in previous clinical trials [20–24], IV serelaxin
ensured adequate exposure of the cervix at a pharmaco-
logical dose and provided an antepartum surge of sere-
laxin of 20-30-fold higher than endogenous relaxin. The
results indicated that while serelaxin was well tolerated,
it did not enhance cervical ripening or affect relevant
clinical parameters, including time to active labour, fre-
quency of spontaneous labour or time to delivery.
Because the results of this study were negative and sere-
laxin was being developed by the study sponsor for an-
other therapeutic indication [34–36], publication of
these data was not a priority and considerable time has
elapsed since the study concluded. There was no em-
bargo on publication and the results were presented at a
meeting (5th International Conference on Relaxin and
Relaxin-Related Peptides, 2008) in timely manner and
published in brief in meeting proceedings [37]. However,
because there is continued interest in the potential abil-
ity of serelaxin to cause cervical ripening [4], the authors
considered these data to be relevant and worthy of
publication.
The negative results in this study may be related
to the natural history of relaxin, which is species-
specific in patterns of expression during pregnancy.
In rodents and pigs, relaxin levels increase at the
end of pregnancy in an antepartum surge of 5-20-
fold mid-pregnancy levels [6] and a relaxin defi-
ciency inhibits the dispersion of cervical collagen fi-
bers that normally occurs during this time [7–9]. In
women, relaxin levels peak during the first trimester
and remain elevated compared to non-pregnancy
levels throughout gestation but an antepartum surge
is not observed [38], perhaps indicating a difference
in relaxin biology relative to cervical ripening among
these species.
Studies in rodents have indicated that relaxin also has
hemodynamic properties starting mid-pregnancy when
levels rise in these species [5]. Serelaxin clinical trials in
other indications or in healthy volunteers have demon-
strated changes in systemic and renal hemodynamics
[34, 39–41], indicating that these effects translate to the
human. There were trends in the current trial suggesting
serelaxin slightly decreased SBP, consistent with this as-
pect of serelaxin pharmacology. Perhaps relaxin’s major
physiological role in human pregnancy relates to mater-
nal hemodynamic adjustments, rather than cervical
ripening.
However, it is also possible that an extended dur-
ation of exposure and/or a higher serelaxin dose
might enhance cervical ripening. A 24-h infusion in
the setting of a clinical trial was estimated to be the
longest duration consistent with management of post-
date pregnant women and the dose tested did achieve
a pharmacologic level that was 20-30-fold higher than
physiologic exposures. Therefore, it is felt that the
trial design afforded a reasonable method to test the
hypothesis of therapeutic serelaxin-mediated cervical
ripening.
Earlier clinical studies reported positive results of top-
ically applied porcine relaxin [20–22], suggesting that
pig relaxin may be more efficacious than human relaxin
in this regard. Receptor (RXFP1) binding studies using
Table 5 Fetal and neonatal adverse events in the all treated
population




Number (%) of Fetuses
Tachycardia 2 (6.3) 1 (2.5)
Hypoxia 3 (9.4) 3 (7.5)
Number (%) of Neonates
Conjunctivitis 4 (12.5) 1 (2.5)
Regurgitation of food 1 (3.1) 3 (7.5)
Cerebral ischemia 8 (25.0) 3 (7.5)
Torticollis 4 (12.5) 2 (5.0)
Hypertonia 3 (8.4) 0 (0.0)
Hypoglycemia 3 (9.4) 2 (5.0)
Jaundice 2 (6.3) 5 (12.5)
Neonatal hypoxia 7 (21.9) 7 (17.5)
Neonatal agitation 7 (21.9) 4 (10.0)
Hypotonia 6 (18.8) 6 (15.0)
Neonatal asphyxia 6 (18.8) 4 (10.0)
Poor weight gain 1 (3.1) 3 (7.5)
Postmature baby 7 (21.9) 1 (2.5)
Umbilical cord around neck 5 (15.6) 3 (7.5)
Dermatitis diaper 3 (9.4) 1 (2.5)
Listed are fetal and neonatal AEs occurring in >5 % in either arm
aThe pooled placebo group includes all fetuses or neonates from Parts A and
B treated with placebo and the pooled serelaxin group includes all subjects
from Parts A and B treated with any dose of serelaxin
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pig relaxin have not supported this hypothesis [41], and
although pig relaxin does bind with higher affinity than
human relaxin to the low affinity serelaxin receptor
(RXFP2), to date this receptor has not been shown to be
expressed in the cervix [42]. That the RXFP2 is the re-
ceptor primarily responsible for cervical ripening in the
human cannot be excluded as a possibility, but serum
serelaxin at the concentrations achieved in this study
should have engaged and activated both RXFP1 and −2.
In summary, this study was well designed and appro-
priate to test the hypothesis in that it was randomized,
double blind and placebo controlled. It was designed to
be a safety and exploratory dose-finding study, and a
safe pharmacological serelaxin dose, whose delivery and
exposure was confirmed by pharmacokinetic testing, was
identified. Limitations included enrollment of small
numbers of subjects from a relatively large number of
institutions and the inability to test longer infusions of
serelaxin. Multiple efficacy endpoints were evaluated to
provide preliminary evidence of efficacy and to deter-
mine appropriate endpoints for further testing in a larger
phase III study. No adjustments for multiplicity were
made within any of the analyses performed; however,
this would not have affected the negative results.
Conclusions
This study indicates that a 24-h exposure to an IV infu-
sion of 75 μg/kg/day serelaxin at the end of pregnancy
was well tolerated by the subjects, fetuses, and neonates,
consistent with the safety profile demonstrated in other
clinical trials under conditions of much greater systemic
exposure [43]. Serelaxin did not advance cervical ripen-
ing or labour.
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